Nuvation Bio’s Safusidenib Receives FDA Fast Track Designation in IDH1-Mutant Glioma

The FDA has granted Fast Track Designation to safusidenib, Nuvation Bio’s investigational oral, brain-penetrant selective inhibitor of mutant IDH1, for the treatment of IDH1-mutant glioma. The regulatory designation comes as the company advances the pivotal Phase 3 SIGMA study and follows durable response data from the Phase 2 J201 trial.

FDA Fast Track Designation Advances Development

Fast Track Designation supports development and regulatory review of therapies for serious diseases with substantial unmet medical need. For safusidenib, the designation allows more frequent interactions with the FDA during development and may enable rolling submission of completed sections of a future marketing application.

Nuvation Bio said the FDA based the designation on data generated across the safusidenib clinical program, including longer-term results from J201. The designation does not establish efficacy or safety and does not guarantee regulatory approval.

Safusidenib Targets Mutant IDH1

Safusidenib is an oral, selective inhibitor of mutant IDH1 that penetrates the brain. IDH1 mutations are common in several glioma subtypes and alter cellular metabolism through production of the oncometabolite 2-hydroxyglutarate (2-HG), which can contribute to abnormal tumor biology.

In the U.S., nearly 2,500 people are diagnosed with IDH-mutant gliomas each year, with more than 95% of these tumors carrying an IDH1 mutation, according to the company. Although IDH1-mutant gliomas generally have a more favorable prognosis than IDH1-wild-type tumors, the disease remains incurable, with outcomes worsening in patients with high-grade or other high-risk features.

Phase 2 Data Support Further Evaluation

The FDA designation follows updated results from the Phase 2 J201 study (NCT04458272). At a median follow-up of 38.8 months, safusidenib produced a confirmed objective response rate of 51.9%.

Median progression-free survival had not been reached, while the 36-month PFS rate was 79.1%. Only one patient who had previously responded subsequently experienced disease progression. Nuvation Bio also reported that longer follow-up identified no new safety signals, supporting the continued assessment of safusidenib’s risk-benefit profile.

The findings build on earlier J201 results published in Neuro-Oncology and provide the clinical basis for advancing the drug into Phase 3 development.

Phase 3 SIGMA Study Tests Maintenance Strategy

The pivotal Phase 3 SIGMA (G203) study (NCT05303519) is evaluating safusidenib versus placebo as maintenance therapy following standard-of-care treatment in patients with IDH1-mutant astrocytoma with high-risk features. The pivotal portion is expected to enroll approximately 300 patients.

SIGMA also includes a separate exploratory, non-pivotal cohort of approximately 40 patients with grade 3 IDH1-mutant oligodendroglioma who have not previously received chemotherapy or radiotherapy. The primary endpoint for this cohort is objective response rate.

Nuvation Bio is also evaluating safusidenib in the Phase 3 G307 study outside the U.S., where vorasidenib is not yet approved or accessible, and in the Phase 2 G209 study in patients previously treated with vorasidenib.

Regulatory Pathway and Next Milestones

Nuvation Bio Founder, President, and CEO David Hung said the company pursued Fast Track Designation to support more rapid development for patients with IDH1-mutant glioma who need additional treatment options.

With SIGMA enrollment underway, the next major milestone will be generation of pivotal Phase 3 data that can determine whether the durable activity observed in earlier studies translates into a clinically meaningful benefit in high-risk IDH1-mutant astrocytoma. The Fast Track designation provides regulatory support as Nuvation Bio advances that program toward potential future FDA review.

Reference

Nuvation Bio Inc. – Nuvation Bio Granted FDA Fast Track Designation for Safusidenib for Treatment of IDH1-Mutant Glioma